RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:97349

Postencephalitic parkinsonism

high confidenceDisorder

Publications

548

65.8th percentile

Trials

0

Interventional, condition-specific

Researchers

943

Distinct authors in sample

Gene link

—

Readiness

3/6

Stages with a signal

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

postencephalitic Parkinsonism · postencephalitic parkinsonism

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    548 matched papers (175 in last 10 years) Source

  3. Phenotype characterisedPresent

    41 HPO annotations (e.g. Resting tremor; Fever; Poor speech) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationPartial

    1 FDA designation (none yet with FDA orphan-indication approval) — e.g. Selegiline HCl Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

41

Associated phenotypes · MONDO:0001945

  • Resting tremor
  • Fever
  • Poor speech
  • Generalized muscle weakness
  • Oculogyric crisis

Showing 5 of 41 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

1

Designation · no FDA orphan-indication approval yet

  • FDA Selegiline HCl (Eldepryl)Idiopathic Parkinson's disease Postencephalitic Parkinsonism Symptomatic parkinsonism · 1984-11-07

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

2

Drugs / clinical candidates · MONDO_0001945

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

548

548 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

548 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

175 in the last 10 years · high confidence · 65.8th percentile (publications denominator)

Phrase hits: 545 · MeSH hits: 3

Open Europe PMC search

Who's working on it?

943

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Lang AE6 papers · 2026

    Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital - UHN, University of Toronto, Toronto, ON, Canada.

    Papers in Europe PMC
  2. 02
    Goedert M5 papers · 2024

    MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

    Papers in Europe PMC
  3. 03
    Hasegawa M5 papers · 2024

    Department of Brain and Neuroscience, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.

    Papers in Europe PMC
  4. 04
    Kovacs GG5 papers · 2026

    Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, Toronto, ON, Canada.

    Papers in Europe PMC
  5. 05
    Vilensky JA5 papers · 2014

    Department of Anatomy and Cell Biology, Indiana University School of Medicine, Fort Wayne, Indiana 46805, USA. vilensk@ipfw.edu

    Papers in Europe PMC
  6. 06
    Bhatia KP4 papers · 2025

    Sobell Department of Motor Neuroscience and Movement Disorders UCL Institute of Neurology London United Kingdom.

    Papers in Europe PMC
  7. 07
    Forrest SL4 papers · 2026

    Tanz Centre for Research in Neurodegenerative Diseases, , ,

    Papers in Europe PMC
  8. 08
    Fox SH4 papers · 2026

    The Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital Toronto Ontario Canada.

    Papers in Europe PMC
  9. 09
    Gilman S4 papers · 2011
    Papers in Europe PMC
  10. 10
    Qi C4 papers · 2024

    Medical Research Council, Laboratory of Molecular Biology, Cambridge CB2 0QH, United Kingdom.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

high confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Postencephalitic parkinsonism — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Postencephalitic parkinsonism"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Parkinson Disease, Postencephalitic

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Postencephalitic parkinsonism" OR "Parkinson Disease, Postencephalitic"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T05:12:35.989Z